AN OBSERVATIONAL COHORT STUDY TO INVESTIGATE THE RISK OF THROMBOEMBOLIC EVENTS IN PATIENTS RECEIVING KCENTRA® OR PLASMA TO REVERSE VITAMIN K ANTAGONIST (VKA) THERAPY IN THE SETTING OF ACUTE MAJOR BLEEDING: